In Part 2, Anna Seekatz, PhD and PhD candidate Sophie Millard highlight the need for precision microbial therapies tailored to host-specific gut environments.
Although COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.
De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
How pharmacists can use shared decision-making to improve antibiotic use.
Findings from a recent phase 3 trial show promising results for the approval of ziresovir in the treatment of respiratory syncytial virus in infants.
With antimicrobial drug shortages expected to continue globally, developing mitigation strategies is essential to prevent complications, including antimicrobial resistance.
The NARROWS framework, developed within the IDSA Core Antimicrobial Stewardship Curriculum, provides a structured, behaviorally informed approach to communication that helps stewardship teams address the social, emotional, and cultural factors influencing prescribing decisions in order to optimize antimicrobial use and combat resistance.
A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
These skills are as critical as ever, and younger clinicians and learners need them to communicate and work professionally.
Biologics have become a novel treatment in recurrent C. difficile.
This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
Advice to community physicians regarding ways to enhance patient-provider relationships and navigate barriers that impact the management of HIV infections.
Ammara Mushtaq, MD, discusses the underrepresentation of different races during the pandemic, but also the newer efforts to include and represent these communities in smaller, local studies.
The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.
Here is a review of using this therapy in this patient population.
Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed.
Lack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.
Andrew Lover, PhD, MPH, discusses the shifting landscape of tick-borne illnesses during Tick-Borne Disease Awareness Month.
Karine G. Le Roch, PhD, discussed her research on a kalihinol analog that combats drug resistance in malaria, emphasizing the need for innovative treatments in the context of climate change and rising transmission rates.
A rare case of Pott puffy tumor occurs in an atypical patient with no risk factors, likely due to untreated sinus infection.
Athena Hobbs, PharmD, BCIDP, looked at this issue through the lens of treating urinary tract infections.
Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.
Clinicians provide an overview of intraamniotic infections and offer treatment strategies for these challenging infections.
Over half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.
The federal government is working to provide greater access to testing and treatment.
In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.
In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.